Altered gene transcription linked to astrocytes and oligodendrocytes in frontal cortex in Creutzfeldt-Jakob disease

Prion. 2018;12(3-4):216-225. doi: 10.1080/19336896.2018.1500076. Epub 2018 Jul 27.

Abstract

Targeted expression of genes coding for proteins specific to astrocytes, oligodendrocytes and myelin was performed in frontal cortex area 8 of Creutzfeldt-Jakob disease methionine/methionine and valine/valine (CJD MM1 and VV2, respectively) compared with controls. GFAP (glial fibrillary acidic protein) mRNA was up-regulated whereas SLC1A2 (solute carrier family 1 member 2, coding for glutamate transporter 1: GLT1), AQ4 (aquaporin 4), MPC1 (mitochondrial pyruvate carrier 1) and UCP5 (mitochondrial uncoupled protein 5) mRNAs were significantly down-regulated in CJD MM1 and CJD VV2, and GJA1 (connexin 43) in CJD VV2. OLIG1 and OLIG2 (oligodendocyte transcription factor 1 and 2, respectively), SOX10 (SRY-Box10) and oligodendroglial precursor cell (OPC) marker NG2 (neuronal/glial antigen) 2 were preserved, but GALC (coding for galactosylceramidase), SLC2A1 (solute carrier family 2 member 1: glucose transporter member 1: GLUT1) and MCT1 (monocarboxylic acid transporter 1) mRNA expression levels were significantly reduced in CJD MM1 and CJD VV2. Expression levels of most genes linked to myelin were not altered in the cerebral cortex in CJD. Immunohistochemistry to selected proteins disclosed individual variations but GFAP, Olig-2, AQ4 and GLUT1 correlated with mRNA levels, whereas GLT1 was subjected to individual variations. However, MPC1, UCP5 and MCT1 decrease was more closely related to the respective reduced neuronal immunostaining. These observations support the idea that molecular deficits linked to energy metabolism and solute transport in astrocytes and oligodendrocytes, in addition to neurons, are relevant in the pathogenesis of cortical lesions in CJD.

Keywords: Creutzfeldt-Jakob disease; astrocytes; astrogliopathy; energy metabolism; myelin; oligodendrocytes; oligodendrogliopathy; prion diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytes / metabolism*
  • Astrocytes / pathology
  • Basic Helix-Loop-Helix Transcription Factors / genetics
  • Basic Helix-Loop-Helix Transcription Factors / metabolism
  • Creutzfeldt-Jakob Syndrome / metabolism*
  • Creutzfeldt-Jakob Syndrome / pathology*
  • Energy Metabolism / genetics
  • Energy Metabolism / physiology
  • Excitatory Amino Acid Transporter 2
  • Frontal Lobe / cytology*
  • Frontal Lobe / pathology
  • Glial Fibrillary Acidic Protein / genetics
  • Glial Fibrillary Acidic Protein / metabolism
  • Glucose Transporter Type 1 / genetics
  • Glucose Transporter Type 1 / metabolism
  • Glutamate Plasma Membrane Transport Proteins / genetics
  • Glutamate Plasma Membrane Transport Proteins / metabolism
  • Humans
  • Mitochondrial Membrane Transport Proteins / genetics
  • Mitochondrial Membrane Transport Proteins / metabolism
  • Mitochondrial Uncoupling Proteins / genetics
  • Mitochondrial Uncoupling Proteins / metabolism
  • Monocarboxylic Acid Transporters
  • Myelin Sheath / genetics
  • Myelin Sheath / metabolism
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Oligodendrocyte Transcription Factor 2 / genetics
  • Oligodendrocyte Transcription Factor 2 / metabolism
  • Oligodendroglia / metabolism*
  • Oligodendroglia / pathology
  • Prion Diseases / genetics
  • Prion Diseases / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Transcription, Genetic / genetics*

Substances

  • Basic Helix-Loop-Helix Transcription Factors
  • Excitatory Amino Acid Transporter 2
  • Glial Fibrillary Acidic Protein
  • Glucose Transporter Type 1
  • Glutamate Plasma Membrane Transport Proteins
  • MPC1 protein, human
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Uncoupling Proteins
  • Monocarboxylic Acid Transporters
  • Nerve Tissue Proteins
  • OLIG1 protein, human
  • OLIG2 protein, human
  • Oligodendrocyte Transcription Factor 2
  • RNA, Messenger
  • SLC1A2 protein, human
  • SLC25A14 protein, human
  • SLC2A1 protein, human

Grants and funding

Part of this work was supported by the Ministry of Economy and Competitiveness, Institute of Health Carlos III (co-funded by European Regional Development Fund, ERDF, a way to build Europe): FIS PI17/00809, IFI15/00035 fellowship to PA-B and co-financed by ERDF under the program Interreg Poctefa: RedPrion 148/16; Institute of Health Carlos III [FIS PI17/00809,].